BRAFV600E Peptide Immunotherapy for Melanoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional pharmaceutical compositions and methods effective for the treatment, prevention, and diagnosis of melanoma, particularly for a large majority of patients with BRAFV600E mutations, as existing solutions are not universally applicable.
Innovation Solution
Development of compositions comprising BRAFV600E-based peptides that induce MHC Class I, HLA-A2-dependent cytotoxic T cell responses, combined with T helper peptides and checkpoint inhibitors, and the use of recombinant dendritic cells pretreated with these peptides or nucleic acid sequences for immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRAFV600E-based peptides are used to induce cytotoxic T cell responses, then therapeutic effectiveness against melanoma is improved, but treatment applicability is limited to patients with specific mutations
Solution Approach 1:
The patent segments the treatment approach by identifying multiple distinct BRAF mutation variants (BRAFV600E, BRAFV600K, BRAFV600R, etc.) and developing specific peptide compositions for each variant. This segmentation allows the treatment to be tailored to different mutation types while maintaining high therapeutic effectiveness for each specific group of patients.
Solution Approach 2:
The patent creates a universal treatment platform that can address multiple BRAF mutation variants through a family of related peptide compositions. By designing peptides that target conserved regions across different BRAF mutants and combining them with checkpoint inhibitors, the treatment achieves broad applicability across melanoma patients with various BRAF mutations while maintaining specificity for each variant.
2Measurement precision
If peptide compositions are used to induce specific immune responses, then treatment specificity is improved, but immune response potency may be insufficient
Solution Approach 1:
The patent merges multiple therapeutic mechanisms by combining peptide compositions that induce antigen-specific cytotoxic T cell responses with checkpoint inhibitor antibodies. This combination therapy integrates targeted antigen recognition with enhanced immune activation, achieving both high treatment specificity and potent immune response. The checkpoint inhibitors remove brakes on the immune system while the peptides provide direction, creating a synergistic effect that overcomes the limitations of either approach alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions induce potent cytotoxic T cell responses and inhibit tumor growth, offering a promising approach for treating melanoma and potentially other cancers with BRAFV600E mutations by enhancing the immune system's targeting capabilities.
Implementation Method 1
BRAFV600E based peptides that induce MHC Class I, HLA-A2-dependent cytotoxic T cell responses
Implementation Method 2
HLA-A2-dependent cytotoxic T cell responses
Implementation Method 3
recombinant dendritic cell that is pretreated ex vivo with a composition containing a BRAFV600E based peptide
Implementation Method 4
an antibody that binds a checkpoint inhibitor or a molecule that mimics the function of a checkpoint inhibitor
Data Source
AI summary
Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.